Posts

November 08, 2014

+
12:27 AM | A Return to Blogging: The Year in Review
After a nearly year absence, Just Me and Eubacteria is back! The past year has been a busy one, not only for science but also for this humble author: I have moved from adjunct positions at several institutions to a full-time professor position at Kingsborough Community College, where I teach several courses (including Microbiology in Health and Disease). I am also engaging in starting my own research projects at the College, with a focus towards translation, synthetic biology, and iGEM. On a […]

November 07, 2014

+
6:48 PM | 6 + 1 Ways Dual-Reporter Assays Can Save Your Data
Transient transfection is often used to perform reporter assays.  We have advocated using a dual-reporter system for decades to normalize the data obtained and gain a clearer understanding of your results.  The experimental reporter should vary with treatment and the control reporter should vary little with treatment. The control reporter thus serves as a marker to […]
+
5:29 PM | Biotech Tweets of the Week (November 3-7)
It seems like each week is crazier than the next in bio-land! Catch up on an action-packed week with the tweets of the week, curated by @23aloha. You can also catch up on previous editions of this feature. Featured tickers: $ACAD $ACHN $ACRX $ACT $AEGR $AET $AEZS $AGIO $ASPX $AVNR $BIOL $BLUE $BMY $CEMP $CLDX $CLVS $CYNAF $DEPO $EPZM $FMI $GNVC $HUM $ICPT $MOH $MRK $NYMX $OXGN $RMTI $RPRX $SLXP $SRPT $TARO $UNH $WLP Note you can use the search box at the upper right to find all BiotechDueDili […]
+
4:59 PM | ctDNA in triple negative breast cancer: a study comparing Illumina & 454 sequencing
A recent circulating tumour DNA (ctDNA) paper describes a comparison of ctDNA to CTC's with respect to TP53 mutations in 40 triple negative breast cancer patients. See: Circulating tumour DNA and circulating tumour cells in metastatic triple negative breast cancer patients in the International Journal of Cancer.The group published a paper earlier in the year (Bidard et al Lancet Oncol 2014) where they counted CTCs before and during treatment in 2000 breast cancers, and reported a high […]
+
3:42 PM | A new meta-analysis on the farm-level impacts of GMOs
Maize breeding, credit: KJHvM Despite the fact that the global area of GM crops has grown rapidly over the past decade and now encompasses more than 170 million hectares it is still questioned whether current applications of genetic engineering in agriculture are beneficial to farmers or not. While several reviews and meta-analyses on the impact of GM crops exist, the evidence is still not regarded as conclusive by many. A new meta-analysis of the agronomic and economic impacts of GMOs has […]
+
2:28 PM | Friday SNPpets
Welcome to our Friday feature link collection: SNPpets. During the week we come across a lot of links and reads that we think are interesting, but don’t make it to a blog post. Here they are for your enjoyment… RT @AwesomeBioTA: Slip of the tongue: Bioinformagics instead of Bioinformatics. But that is pretty on-point for […]
+
2:13 PM | Right Turn: Seeing the potential of retinal stem cells
> The well known expression that “the eyes are the gateway to the soul” has tragic connotations in the context of retinal disease. Rhetoric aside, the potential for regenerative medicine to improve our ability to treat ocular disease and injury makes it an exciting area of stem cell research. It is also one that has...Read more
+
11:41 AM | Eisai "speechless" as G-BA denies price premium for Fycompa
But company has better news on cancer drug Halaven
+
10:24 AM | Shire drawn into Luxembourg tax haven exposé
Firm is one of 340 companies identified in report by ICIJ
+
10:24 AM | Novartis faces FDA rejection for myeloma drug
Concerns over toxicity of panobinostat
+
6:41 AM | Perrigo expands consumer health with €3.6bn Omega purchase
Follows takeover of Elan last year
+
12:15 AM | Hamell Communications adds to team
Comms agency has steadily expanded team this year
+
12:15 AM | Saatchi & Saatchi expands team
Includes two new associate creative directors

November 06, 2014

+
9:30 PM | Journal Watch - Oncology edition
A new round-up of recent open-access articles from the scientific and medical literature. The theme today is cancer research, clinical trials, and drug development. Check out previous cancer-themed reading lists as well. A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor ActivityList et al. Molecular Cancer Therapeutics.Going a step beyond the antibody-drug conjugate (ADC)...New Strategies in Ovarian Cancer: Translating the Molecular […]
+
8:29 PM | Rehab Science Parody
Tweet This Post
+
5:11 PM | Don’t Silence Science, an Appeal
Today, we have an unfortunate announcement to make. For about one month, Biology Fortified has been the target of an ongoing Denial of Service attack, which has been taking our sites offline. We have prepared a video announcement to tell you more about it, and to make an appeal to the attacker for them to stop trying to take down our site. We are seeking the support of our readers and everyone else who agrees that this kind of attack has no place in debates about science. A 13-second snapshot […]
+
2:19 PM | What’s The Answer? (biggest challenges)
Biostars is a site for asking, answering and discussing bioinformatics questions and issues. We are members of the community and find it very useful. Often questions and answers arise at Biostars that are germane to our readers (end users of genomics resources). Every Thursday we will be highlighting one of those items or discussions here […]
+
2:17 PM | Eman Reports From Ebola Ground Zero
The last post here at DNA Science continued Emmanuel Gokpolu’s reporting from Ebola ground zero in Monrovia, and surrounding communities. The Ebola outbreak interrupted Eman’s medical education, so now he is teaching his people about strategies to minimize risk of infection. Eman … Continue reading »The post Eman Reports From Ebola Ground Zero appeared first on DNA Science Blog.
+
12:05 PM | Nexium windfall lifts AZ in third quarter
Still to feel effects of generic competition
+
12:04 PM | Extra stomach cancer indication for Cyramza in US
FDA backs Lilly drug in combination with paclitaxel chemotherapy
+
12:01 PM | Vertex submits Kalydeco combo for cystic fibrosis
Seeks approval in both US and Europe
+
11:35 AM | GSK first to file IL-5 antagonist for asthma
Mepolizumab submitted as a treatment for severe eosinophilic asthma
+
12:16 AM | New CEO for Grayling Germany
Frank Schönrock joins from Grünenthal
+
12:15 AM | Publicis Healthcare appoints global business development head
Rick Keefer was CEO of Publicis Touchpoint Solutions
+
12:02 AM | Power to the people: an era of self-care
Pharma should consider what a patient-centric approach to care really means

November 05, 2014

+
9:34 PM | Small words = big ideas
Explaining science is a tricky business. You have to use the right words to be accurate, and you have to assume that your audience may never have heard those words. Recently, I was invited [More...]
+
9:04 PM | Author of Vampire Diaries vilifies antivaccine parents
I’m going to admit that I don’t read “young adult” novels. I don’t even watch “young adult” movies, though that line is kind of murky. I don’t want my vampires to be sparkly and play baseball. And I don’t want my post-apocalyptic future to exclude zombies. One of the more popular horror/teen romance/vampire series of novels is The […]Continue reading «Author of Vampire Diaries vilifies antivaccine parents»
+
8:00 PM | A Great Resource for Scientists Looking for a Career Change
Cruising through the blogosphere yesterday, I happened upon an interesting blog whose primary focus is to show academic scientists how to enter industry. The Cheeky Scientist was started by Isaiah Hankel, an immunology PhD graduate from the University of Iowa who had the fortune of working at several well known life science companies (including Bio-Rad […]
+
4:00 PM | Silencing Diabetes
While Type 1 diabetes (T1D) is an autoimmune disorder characterized by the destruction of pancreatic cells, Type 2 (T2D) is defined as deficient insulin production and impaired insulin action. This is why the two can be distinguished from each other through an antibody screening. The exact cause of β cell ... The post Silencing Diabetes appeared first on EpiBeat.
+
3:26 PM | 250bp paired-end on your HiSeq 2500...up yours X Ten ;-)
The 250bp paired-end HiSeq rapid run kits are almost here! Expect to get 150M reads per lane or more on the current rapid flowcells. What will you do with 150M 500bp OPES?No word on pricing yet, and I could not find any PE250 data on BaseSpace. Looking forward to finding out more...Update: pricing on PE250! I was sent some data on the PE250 and a lane is going to cost $2869 (see below), expect to get >75% of bases >Q30 at 2x250b. Sounds pretty cool. How many of these we'll run in a year […]
123456789
274 Results